July 20, 2025 a 08:38 pm
AMGN: Analysts Ratings - Amgen Inc.
Amgen Inc. experiences a mix of analyst ratings, reflecting a strong foundation in pharmaceuticals with broad therapeutic targets. The focus on human therapeutics and established partnerships in the healthcare sector underscores its market resilience and potential for growth. However, analysts have shown a tendency to lean towards holding positions, indicating a cautious approach amid industry challenges.
Historical Stock Grades
The following table displays the most recent analyst ratings for Amgen Inc., highlighting a tendency towards neutral positions.
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 5 | |
| Buy | 11 | |
| Hold | 14 | |
| Sell | 2 | |
| Strong Sell | 1 |
Sentiment Development
Recently, Amgen's analyst ratings exhibit a steady increase in hold recommendations, while buy ratings remain consistent. A slight decline in strong buy recommendations suggests growing caution among analysts.
- Hold ratings have seen a gradual increase over the last few months.
- Strong Buy recommendations have decreased marginally, indicating caution.
- The overall sentiment remains largely stable but with a trend towards more conservative positions.
Percentage Trends
Since the beginning of 2024, notable shifts in analyst sentiment have been observed. The share of buy ratings is stable, but the relative increase in hold positions is evident, suggesting more analysts opt for a reserved stance.
- Strong Buy ratings decreased from 6 in 2024 to 5 in 2025.
- Hold ratings increased, while Buy ratings stayed stable.
- Maintained Sell and Strong Sell positions show persistent caution in the market outlook.
- Overall, analysts show a conservative trend by shifting towards hold ratings.
Latest Analyst Recommendations
Recent recommendations highlight a maintained position by analysts, aligning with the general trend of stability in Amgen's outlook.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-06-27 | Overweight | Overweight | Piper Sandler |
| 2025-06-24 | Neutral | Neutral | Cantor Fitzgerald |
| 2025-05-16 | Overweight | Overweight | Piper Sandler |
| 2025-05-07 | Neutral | Neutral | Mizuho |
| 2025-05-02 | Neutral | Neutral | UBS |
Analyst Recommendations with Change of Opinion
In recent quarters, several shifts in analyst opinions have been observed, indicating adjustments in market outlooks.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2024-10-14 | Hold | Buy | Truist Securities |
| 2024-08-07 | Equal Weight | Overweight | Wells Fargo |
| 2024-05-03 | Outperform | Market Perform | William Blair |
| 2024-05-03 | Equal Weight | Underweight | Barclays |
| 2023-12-21 | Buy | Neutral | Daiwa Capital |
Interpretation
The current market sentiment for Amgen Inc. is one of cautious optimism. While there is a consistent hold recommendation growth, indicating prudence, this does not appear to reflect a substantial decline in confidence in Amgen's overall market position. Instead, it signifies a market standing characterized by certain stability, where changes might be reflective of sector-wide adjustments rather than company-specific concerns. Analysis suggests that while volatility in recommendations is present, it is often contained within a narrow range, affirming confidence in Amgen's long-term fundamentals while being mindful of immediate uncertainties.
Conclusion
Amgen Inc. positions itself robustly in a competitive pharmaceuticals landscape, underlined by its broad therapeutic areas and strategic partnerships. Despite the challenge of a shifting analyst sentiment, predominantly towards hold ratings, the data implies a basis for cautious optimism rather than adverse market perceptions. The realignment of analyst ratings might reflect broader market conditions and changes in industry dynamics rather than explicit weaknesses in Amgen’s financial health or strategic direction. Moving forward, Amgen's robust portfolio and pipeline, combined with strategic partnerships, could offer a counterbalance to analyst reservations, making it a potential candidate for longer-term investment considerations.